Trillium Therapeutics Inc

Trillium Therapeutics — Investor Day (April 2021)

112 slides from Trillium Therapeutics's investor day presentation, Apr 28, 2021

  1. Slide 1: R&D Day: Opening a New Chapter in Trillium's Evolution

    R&D DAY OPENING A NEW CHAPTER IN TRILLIUM’S EVOLUTION April 28, 2021

  2. Slide 2: Forward-Looking Statements Safe Harbor

    2 FORWARD-LOOKING STATEMENTS SAFE HARBOR This presentation contains forward-looking statements within the meaning of applicable securities laws including the Private Securities Litigation Reform Act of 1995, as amended. All statements contained herein that are not clearly historical in nature are fo

  3. Slide 3: Meeting Objectives

    3 MEETING OBJECTIVES • Provide data update on TTI-622/621 since ASH20, and new insights into TTI-621 MoA • Discuss what makes TTI-622/621 potentially best-in-class CD47 blockers, and the Foundation we have built • Announce the Next Chapter - outline strategic priorities and clinical development plan

  4. Slide 4: Today's Presenters

    4 TODAY’S PRESENTERS Jan Skvarka Chief Executive Officer GUEST SPEAKERS Ingmar Bruns Chief Medical Officer Rose Harrison Senior Vice President, Corp Dev & Strategy Bob Uger Chief Scientific Officer Naval Daver MD Anderson Alex Lesokhin MSKCC Krish Patel Swedish Cancer Institute

  5. Slide 5: Plan for the Day

    5 CLINICAL UPDATE NEXT CHAPTER INTRODUCTION & HIGHLIGHTS WRAP-UP • 622/621 scientific overview • 622 program update • 621 program update • The Foundation we have built • Strategic priorities and clinical development plan PLAN FOR THE DAY Q&A 1 Q&A 2

  6. Slide 6: T-Cell CPIs Are Revolutionizing Cancer Treatment, But Only Minority of Patients Benefit

    6 T-CELL CPIS* (FIRST GEN IMMUNOTX) ARE REVOLUTIONIZING CANCER TREATMENT, BUT ONLY MINORITY OF PATIENTS BENEFIT Immune System Adaptive T cell CPIs • 2018 Nobel Prize • Cure for meaningful % of cancer patients • Largest drug class by 2025 *CPIs – Checkpoint Inhibitors §Source: Global data Source: Nat

  7. Slide 7: Innate Immunity and CD47 Emerging as Next Frontier in Immunotherapy

    7 INNATE IMMUNITY, AND CD47 SPECIFICALLY, ARE EMERGING AS THE NEXT FRONTIER IN IMMUNOTHERAPY Immune System Adaptive Innate T cell CPIs Macrophage CPIs • 2018 Nobel Prize • Cure for meaningful % of cancer patients • Largest drug class by 2025 • CD47 – Dominant innate checkpoint • Target validation in

  8. Slide 8: Trillium Therapeutics at a Glance

    8 Leading clinical-stage immuno-oncology company focused on CD47, a checkpoint of the innate immune system TWO DIFFERENTIATED CD47 (SIRPαFc) ASSETS WITH MONOTHERAPY PoC : MULTIPLE SHOTS ON GOAL – BROAD P1B/2 PROGRAM INITIATED ORGANIZATION SET UP FOR SUCCESS • Potentially class-leading monotherapy ac

  9. Slide 9: Trillium Molecules Differentiated From Other CD47 Agents

    9 TRILLIUM MOLECULES ARE DIFFERENTIATED FROM OTHER CD47 AGENTS ON SEVERAL DIMENSIONS Candidate TTI-621 TTI-622 Magrolimab ALX148 Lemzoparlimab AO-176 SL-172154 Molecule WT SIRPαFc fusion protein WT SIRPαFc fusion protein CD47 mAb High aff. SIRPαFc fusion protein CD47 mAb CD47 mAb WT SIRPα-Fc-CD40L f

  10. Slide 10: New Data Since ASH20: Emerging Drug Profiles

    10 NEW DATA SINCE ASH20 EMERGING DRUG PROFILES 622 • 1 CR + 2 PRs at 12 & 18 mg/kg • No MTD reached, no DLTs at 12 & 18 mg/kg • CD47 blockade proposed MoA • 33% ORR* at doses 0.8-18 mg/kg in R/R lymphomas • Very well tolerated • 8 mg/kg selected as P1b/2 starting dose** 621 • NK cells contributing t

  11. Slide 11: Robust Foundation for Advancing Into P1b/2

    11 ROBUST FOUNDATION FOR ADVANCING INTO P1B/2 Monotherapy PoC in hemes (weekly dosing) Combination regimens Solid tumors Q2/3W dosing + • PK data • 622: Anecdotal clinical evidence (2 CR pts on Q3/4W dosing) • 622: Dose escalated to 18 mg/kg weekly (P1b/2 dose declared at 8 mg/kg weekly) • Low molec

  12. Slide 12: Priorities Going Forward

    12 PRIORITIES GOING FORWARD: (1) TWO DRUG CANDIDATES; (2) SEVEN INDICATIONS; (3) MULTIPLE COMBINATIONS • Prioritize First in Class and/or Best in Class • Consider potential for fast PoC & accelerated development paths AIM FOR LEADERSHIP • Macrophage & CD47 involvement • Preclinical and/or clinical P

  13. Slide 13: Pipeline: Initiating P1b/2 Studies in Nine Settings

    13 PIPELINE: INITIATING P1B/2 STUDIES IN NINE SETTINGS PROGRAM INDICATION COMBINATION AGENT STAGE OF DEVELOPMENT SPONSOR STATUS PRECLINICAL IND ENABLING EARLY-STAGE CLINICAL LATE-STAGE CLINICAL 622 MM Carfilzomib+dex Trillium First patient dosed AML p53 mut. Azacitidine Trillium Enrolling AML unfit

  14. Slide 14: Transformation Program in 2020 Set the Stage

    14 STRATEGY CLINICAL DEVELOPMENT GOVERNANCE** LEADERSHIP** ADVISORY INFRASTRUCTURE** INVESTOR BASE WIDE-RANGING TRANSFORMATION PROGRAM IN 2020 SET THE STAGE FOR OUR NEXT CHAPTER + Discontinued lead IT CTCL* program + Refocused on large heme and solid tumors via IV administration + Substantially adva

  15. Slide 15: Board and Trillium Leadership

    15 BOARD TRILLIUM LEADERSHIP Luke Beshar Rose Harrison SVP, Corp Dev & Strategy Jan Skvarka CEO Paul Walker Helen Tayton-Martin Kathleen Large SVP, Clin Ops Ingmar Bruns CMO Penka Petrova CDO Ben Looker GC Bob Uger CSO James Parsons CFO Jan Skvarka Mike Kamarck Paolo Pucci Scott Myers Joined since S

  16. Slide 16: World-Class Advisory Infrastructure

    16 WORLD-CLASS ADVISORY INFRASTRUCTURE … AND CREDITS FOR OUR STRATEGY SCIENTIFIC ADVISORY BOARD (SAB) AML KOL Panel Lymphoma KOL Panel Ovarian KOL Panel • John Byrd, Ohio • Harry Erba, Duke • Naval Daver, MD And. • James Foran, Mayo • Amir Fathi, MGH • Tracy Murphy, UoT • Haider Mahdi, Cleveland • U

  17. Slide 17: Agenda

    17 • 622/621 scientific overview • 622 program update • 621 program update • The Foundation we have built • Strategic priorities and clinical development plan AGENDA CLINICAL UPDATE NEXT CHAPTER INTRODUCTION & HIGHLIGHTS WRAP-UP Q&A 1 Q&A 2

  18. Slide 18: Tumors Use CD47 Don't Eat Me Signal

    18 TUMORS USE CD47 “DON’T EAT ME” SIGNAL TO EVADE DESTRUCTION BY INNATE IMMUNE SYSTEM CD47 Pathway in Cancer Don’t eat me signal DON’T EAT ME CD47 blockade emerging as a next-generation checkpoint inhibitor strategy in immuno-oncology • Many hematologic and solid tumors express high levels of CD47 •

  19. Slide 19: Macrophage Activation Requires CD47 Blockade and Eat Me Signal

    19 MACROPHAGE ACTIVATION REQUIRES BOTH CD47 BLOCKADE AND DELIVERY OF AN “EAT ME” SIGNAL • CD47 blockade alone is not sufficient to trigger macrophage anti-tumor activity • Macrophages must also receive an “eat me” (pro-phagocytic) signal • IgG1 Fc delivers a strong “eat me” signal, IgG4 Fc a moderat

  20. Slide 20: TTI-622 and 621: Two Novel CD47 Blocking Agents

    20 622 & 621: TWO NOVEL CD47 BLOCKING AGENTS WITH BUILT-IN ACTIVATING SIGNALS TTI-622 TTI-621 (SIRPα-IgG4 Fc) (SIRPα-IgG1 Fc) SIRPα domain: Blocks CD47 DON’T EAT ME signal IgG4 Fc: Delivers moderate EAT ME signal IgG1 Fc: Delivers strong EAT ME signal & activates NK cells Designed to: • Achieve high

  21. Slide 21: Proposed Mechanisms of Action

    21 PROPOSED MECHANISMS OF ACTION

  22. Slide 22: Preclinical Support for Distinct Mechanisms of Action

    22 PRECLINICAL SUPPORT FOR DISTINCT MECHANISMS OF ACTION Both 622 and 621 trigger tumor cell phagocytosis by macrophages; no activity with an inert Fc 621 (but not 622) triggers NK- mediated tumor cell killing Phagocytosis of primary AML cells by human macrophages in the presence of TTI-622, TTI-621

  23. Slide 23: 622 & 621 Do Not Bind to Red Blood Cells

    23 622 & 621 DO NOT BIND TO RED BLOOD CELLS (RBCS) TTI-621 control Fc (IgG1) TTI-622 control Fc (IgG4) BRIC126 2D3 CC2C6 B6H12 5F9 mIgG1 mIgG2b 10 0 10 1 10 2 10 3 10 4 10 5 10 6 CD47 mAbs mAb Controls Mean Fluorescence Intensity 622 & 621 do not bind human RBCs1 1Results confirmed by independent gr

  24. Slide 24: Scientific Overview: Key Takeaways

    24 SCIENTIFIC OVERVIEW: KEY TAKEAWAYS CD47 is a “don’t eat me” signal that many tumor cells use to evade killing by macrophages 1 However, blocking CD47 alone is not sufficient to engage macrophages; an “eat me” signal must also be present 2 Trillium has two CD47 blocking agents with built-in activa

  25. Slide 25: Agenda

    25 • The Foundation we have built • Strategic priorities and clinical development plan AGENDA CLINICAL UPDATE NEXT CHAPTER INTRODUCTION & HIGHLIGHTS WRAP-UP Q&A 1 Q&A 2 • 622/621 scientific overview • 622 program update • 621 program update

  26. Slide 26: TTI-622-01 Study Overview

    26 TTI-622-01 STUDY OVERVIEW As of 12 April 2021 data cutoff date; data are subject to change prior to final database lock *One Erdheim-Chester patient is not included in ITT count, but is included in safety analysis (N=43) Abbreviations: ITT – Intent to Treat; RE – Response Evaluable 0.05-0.05-0.1

  27. Slide 27: TTI-622 Is Well Tolerated

    27 622 IS WELL TOLERATED • Well tolerated • No infusion-related reactions • Related high-grade AEs were rare and limited to transient cytopenias • Most common unrelated AEs were mild constitutional and gastrointestinal symptoms • All other related AEs occurred in <10% of patients Adverse Events Tota

  28. Slide 28: Monotherapy Activity in Multiple Lymphoma Indications, 33% ORR

    28 622 MONOTHERAPY ACTIVITY OBSERVED IN MULTIPLE LYMPHOMA INDICATIONS, WITH 33% ORR Indication Response evaluable N CR PR OR DLBCL 11 1 (9%) 2 (18%) 3 (27%) PTCL 6 0 (0%) 2 (33%) 2 (33%) CTCL 4 1 (25%) 2 (50%) 3 (75%) FL 3 0 (0%) 1 (33%) 1 (33%) HL 3 0 (0%) 0 (0%) 0 (0%) TOTAL 27 2 (7%) 7 (26%) 9 (3

  29. Slide 29: Monotherapy Activity Across Broad Dose Range; P1b/2 Dose Set

    29 MONOTX ACTIVITY OBSERVED ACROSS BROAD TX RANGE IN HEAVILY PRE-TREATED PATIENTS; P1B/2 DOSE SET AT 8 MG/KG COHORT & MAX DOSE ORR (ITT) ORR (RE) RESPONDER CHARACTERISTICS INDICATION PRIOR LINES OF THERAPY BEST RESPONSE FIRST RESPONSE PATIENT STATUS 0.8 mg/kg 1/4 (25%) 1/3 (33%) DLBCL 4 CR PR wk 8 C

  30. Slide 30: Observed Single Agent Activity

    30 622 OBSERVED SINGLE AGENT ACTIVITY CR PR SD PD TTI-622-01: Target Lesion Change (%) at Dose Levels 0.8-18 mg/kg Response Evaluable Patients (n) Best Response (n) ORR in Evaluable Patients CR PR OR 27 2 7 9 33% PMR PMR PMR PMR NL NL NL NL NL DLBCL (8) DLBCL (1) DLBCL (8) FL (12) DLBCL (8) FL (0.8)

  31. Slide 31: Responders Showed Consistently Fast Onset of Action

    31 RESPONDERS SHOWED CONSISTENTLY FAST ONSET OF ACTION * * * * * * * * * → Ongoing → Ongoing → Ongoing → Ongoing PD following 3 week interruption due to unrelated AE Off study due to intercurrent illness → Ongoing → Ongoing → Ongoing 90 180 DLBCL (0.8) DLBCL (12) CTCL (8) PTCL (18) DLBCL (4) DLBCL (

  32. Slide 32: Responder Profile #1: CR in DLBCL

    32 RESPONDER PROFILE #1: CR IN DLBCL @ 0.8 MG/KG 78 y/o male with non-GCB DLBCL o Stage IV; multiple lesions in musculature of upper extremities, m. ileopsoas, right scapula, right axillary lymph node o Several target lesions in left shoulder Prior lines of therapy: 1. R-EPOCH/R-CEOP, from 12/15 til

  33. Slide 33: Responder Profile #5: PR in FL

    33 RESPONDER PROFILE #5: PR IN FL @ 8.0 MG/KG Response Treatment length Current status PR (wk 8) 15 weeks 8.0 mg/kg Discontinued due to PD 68 y/o female with Follicular Lymphoma o Stage III; bulky lesions in the neck, chest, abdomen/pelvis, bone marrow involvement o Target lesions in the periaortic

  34. Slide 34: Responder Profile #8: CR in CTCL

    34 RESPONDER PROFILE #8: CR IN CTCL @ 18 MG/KG Response Treatment length Current status CR (wk 8, after 2 doses) 12 weeks 18.0 mg/kg Ongoing (Q3W dosing) Baseline Week 8 37 y/o female with Mycosis Fungoides with large cell transformation o Stage IV o Target lesions periportal/peripancreatic, and abd

  35. Slide 35: Responder Profile #9: PR in DLBCL

    35 RESPONDER PROFILE #9: PR IN DLBCL @ 18 MG/KG Response Treatment length Current status PR (wk 8) 11 weeks 18.0 mg/kg Active 65 y/o male with DLBCL (T-cell rich large B-cell lymphoma) o Stage IV o Target lesions in paraaortic, paratracheal, peripancreatic and cervical lymph nodes and in the hilar a

  36. Slide 36: TTI-622 Exhibits Predictable PK

    36 622 EXHIBITS PREDICTABLE PK THAT SUPPORTS EVALUATING LESS FREQUENT ADMINISTRATION Week 1 Concentration Profiles of Serum TTI-622 Following IV Infusion (Mean ± SD) Week 6 Concentration Profiles of Serum TTI-622 Following IV Infusion (Mean ± SD) • Dose proportional increase in serum TTI-622 exposur

  37. Slide 37: Dose-Dependent Increases in Receptor Occupancy

    37 622 EXHIBITS DOSE-DEPENDENT INCREASES IN RECEPTOR OCCUPANCY (RO) ON PERIPHERAL BLOOD T CELLS 0 20 40 60 80 100 0.05, 0.05, 0.1 mg/kg % RO 0 D7 0 D7 0 D7 Week 1 Week 6 Week 12 0 20 40 60 80 100 0.2, 0.2, 0.3 mg/kg % RO 0 D7 0 D7 0 D7 Week 1 Week 6 Week 12 0 20 40 60 80 100 0.4, 0.4, 0.8 mg/kg % RO

  38. Slide 38: 622-01 Study: Key Takeaways

    38 622-01 STUDY: KEY TAKEAWAYS 1 2 33% (9/27) monotherapy ORR in response evaluable R/R all-comer lymphoma patients at doses 0.8-18 mg/kg - Highly pre-treated patients, with median 4 (2-10) prior therapies - 2 CRs + 7 PRs, with 3 patients at 18 mg/kg pending wk 8 assessment - Fast onset of action (a

  39. Slide 39: Agenda

    39 • The Foundation we have built • Strategic priorities and clinical development plan AGENDA • 622/621 scientific overview • 622 program update • 621 program update CLINICAL UPDATE NEXT CHAPTER INTRODUCTION & HIGHLIGHTS WRAP-UP Q&A 1 Q&A 2

  40. Slide 40: Intratumoral Injections in CTCL Induced Rapid Lesion Reductions

    40 INTRATUMORAL 621 INJECTIONS IN CTCL INDUCED RAPID LESION REDUCTIONS AND PROVIDED INITIAL POC *CAILS - Composite Assessment of Index Lesion Severity, a measure of local lesion responses Data as of 31 Mar 2020 (database lock date) Baseline Week 4 85M with stage IIB Mycosis Fungoides with large cell

  41. Slide 41: Intravenous TTI-621 Overview

    41 INTRAVENOUS TTI-621 OVERVIEW: OVER 200 PATIENTS TREATED Dosing (mg/kg) Monotherapy Indications Combination Indications *Most patients dosed at 0.2 mg/kg; some patients dose-intensified up to 0.5 mg/kg per investigator discretion **Simon 2-stage design study; Stage 1 completed; Stage 2 on hold and

  42. Slide 42: Monotherapy Activity in T and B-Cell Lymphoma

    42 621 MONOTHERAPY ACTIVITY OBSERVED IN T AND B-CELL LYMPHOMA INDICATIONS Indication Response evaluable n CR PR OR CTCL 62 2 (3%) 10 (16%) 12 (19%) PTCL 22 2 (9%) 2 (9%) 4 (18%) DLBCL 7 1 (14%) 1 (14%) 2 (29%) Based on the data in clinical database as of 12 Apr 2021; data are subject to change prior

  43. Slide 43: TTI-621 Has Good Tolerability and Manageable Toxicities

    43 621 HAS GOOD TOLERABILITY AND MANAGEABLE TOXICITIES • Acceptable tolerability with transient and manageable toxicities • IRRs occur mostly at first dose and are very manageable with prophylactic treatment • No dose dependent increase in frequency of thrombocytopenia, but increasing magnitude of p

  44. Slide 44: Part 4 Dose Escalation Study With IV TTI-621

    44 PART 4 OF THE ONGOING DOSE ESCALATION STUDY WITH INTRAVENOUS TTI-621 EXPLORES HIGHER DOSES 0.5 mg/kg 0.7 mg/kg 1.0 mg/kg 1.4 mg/kg 2.0 mg/kg • Phase 1b Dose Optimization (3+3 schema) of single agent TTI-621 weekly IV in advanced R/R CTCL (NCT02663518) • Primary objectives: Further evaluate safety

  45. Slide 45: Improvement of Skin Lesions and Durable Responses in CTCL

    45 IMPROVEMENT OF SKIN LESIONS AND DURABLE RESPONSES IN CTCL PATIENTS Tumor (n) Response Evaluable n (%) Treatment Duration in Responders (days) med (min-max) Time to Response (days) med (min-max) CR PR OR MF (41) 0 9 (22) 9 (22) 135 (41-1170) 57 (23-218) SS (21) 2 (10) 1 (5) 3 (14) 309 (185-1199) 1

  46. Slide 46: Responder Profile #1: PR in SS

    46 RESPONDER PROFILE #1: PR IN SS @ 0.5 MG/KG Screening Week 16 69 y/o female with Sézary Syndrome (SS) o Stage IVA2; T4N1M0B2 o Lymph node lesions present in axilla and pelvic regions Prior lines of therapy: 1. Bexarotene, from 01/16 till [unknown] 2. Extracorporal Photopheresis, 03/18 3. Narrow Ba

  47. Slide 47: Responder Profile #2: PR in MF

    47 RESPONDER PROFILE #2: PR IN MF @ 2.0 MG/KG Response Treatment length PR (wk 16) 16 weeks 2.0 mg/kg Active 74 y/o male with Mycosis Fungoides (MF) o Stage IVA1; T4N0M0B2 Prior lines of therapy: 1. Photopheresis, from 06/19 till 07/20 2. Dupixent, from 12/19 till 04/20, TF (treatment failure) 3. Vo

  48. Slide 48: TTI-621 Exhibits Predictable PK

    48 621 EXHIBITS PREDICTABLE PK THAT SUPPORTS EVALUATING LESS FREQUENT ADMINISTRATION For trough figure, n = subjects at Week 2; some time points may have fewer subjects NOTE: 0.05-0.3 mg/kg are from Part 1 (dose escalation phase); 0.5 - 2.0 mg/kg are from Part 4 (dose optimization phase). Week 6 Con

  49. Slide 49: NK Cell Activation May Contribute to Anti-Tumor Activity

    49 NK CELL ACTIVATION MAY CONTRIBUTE TO 621 ANTI-TUMOR ACTIVITY Increased NK cell infiltration in tumor biopsies observed after 621 treatment NK cells (CD56+) detected by IHC analysis of tumor biopsies from an MF patient achieving a PR following IV 1 mg/kg TTI-621 (Study 621-01, Part 4). The CD4 sta

  50. Slide 50: 621-01 Study: Key Takeaways

    50 621-01 STUDY: KEY TAKEAWAYS Unique and highly differentiated proposed MoA, combining CD47 blockade and NK cell activation 1 2 3 No MTD reached at doses up to 2 mg/kg; manageable IRRs and transient thrombocytopenia observed, though not dose limiting 4 18-29% monotherapy ORR in response evaluable B

  51. Slide 51: Q&A

    51 Q&A pt 1 Chief Executive Officer Jan Skvarka Chief Medical Officer Ingmar Bruns Chief Scientific Officer Bob Uger Key Opinion Leader Krish Patel

  52. Slide 52: Agenda

    52 • The Foundation we have built • Strategic priorities and clinical development plan AGENDA • 622/621 scientific overview • 622 program update • 621 program update CLINICAL UPDATE NEXT CHAPTER INTRODUCTION & HIGHLIGHTS WRAP-UP Q&A 1 Q&A 2

  53. Slide 53: All Top Oncology Drugs Have Single Agent Activity

    53 ALL TOP ONCOLOGY DRUGS HAVE SINGLE AGENT ACTIVITY (including 17/20 with monotherapy use indicated in FDA label) Top 10 oncology drugs Top 11-20 oncology drugs Drug 2019 sales $B Indicated use (per label) Demonstrated single agent activity if not per label? Combo Mono 11 Tagrisso 3.2 n/a 12 Darzal

  54. Slide 54: Best-in-Class Single Agent Response Rates in CD47 Field

    54 622 & 621 HAVE OBSERVED POTENTIALLY BEST-IN-CLASS SINGLE AGENT RESPONSE RATES IN THE CD47 FIELD • 1NCT02216409; Sikic, JCO 2019 • 3NCT03013218; Lakhani, ASCO • 4NCT02641002; Zeidan, ASH 2019 • 2NCT03248479; ASCO 2019 • 1NCT02216409; Sikic, JCO 2019 • 3NCT03013218; Lakhani, ASCO 2018 • 2NCT0324847

  55. Slide 55: Comparable Monotherapy ORRs in R/R DLBCL

    55 IN R/R DLBCL, 622 & 621 OBSERVED COMPARABLE MONOTX ORRs AS MAGRO & ALX148 IN COMBINATION WITH RITUXAN 36% (21/59) 1Roschewski, EHA 2019 30 10 2Kim, EHA 2020 Magro + Rtx1 TTI-621 DLBCL Monotherapy ALX148 + Rtx2 27% (3/11) 0.8-18 TTI-622 0% 20% 40% 60% 80% ORR 29% (2/7) ≤0.5 Dose (mg/kg): *These tr

  56. Slide 56: Combination Potential With Chemotherapies & Small Molecules

    56 622/621 HAVE SHOWN COMBINATION POTENTIAL WITH CHEMOTHERAPIES & SMALL MOLECULES (PRE-CLINICAL DATA) CD47 sensitive cell lines CD47 insensitive cell lines Macrophage phagocytosis of human tumor cell lines AML-2 (azacitidine, venetoclax), MM1S (carfilzomib), OVCAR3 (paclitaxel), UWB1.289 BRCA1- null

  57. Slide 57: 622/621 Combine With Antibodies

    57 622/621 COMBINE WITH ANTIBODIES, REGARDLESS OF IgG BACKBONE 0 20 40 60 0 500 1000 1500 2000 TTI-622 + Cetuximab Days post inoculation Tumor Volume (mm 3 ) Vehicle 622 Ctx Ctx + 622 0 20 40 60 0 500 1000 1500 2000 TTI-621 + Cetuximab Days post inoculation Tumor Volume (mm 3 ) Vehicle 621 Ctx Ctx +

  58. Slide 58: Anti-Tumor Activity in Skin of CTCL Patients

    58 ANTI-TUMOR ACTIVITY OBSERVED IN SKIN OF CTCL PATIENTS, SUGGESTING 621/622 ABILITY TO PENETRATE SOLID TUMORS 0% 10% 20% 30% 40% 50% 621.0 622.0 Response rate (mSWAT) 621 IT 621 IV 26% (14/54) 23% (6/26) 621 delivered intratumorally and intravenously showed comparable response rates in skin lesions

  59. Slide 59: Foundation: Key Takeaways

    59 FOUNDATION: KEY TAKEAWAYS Strong basis for combination therapies, supported by preclinical evidence with a diverse set of therapeutic agents 2 Potentially class-leading monotherapy activity demonstrated by both 622 & 621 across multiple heme malignancy indications 1 Strong basis for solid tumors,

  60. Slide 60: Agenda

    60 • The Foundation we have built • Strategic priorities and clinical development plan AGENDA • 622/621 scientific overview • 622 program update • 621 program update CLINICAL UPDATE NEXT CHAPTER INTRODUCTION & HIGHLIGHTS WRAP-UP Q&A 1 Q&A 2

  61. Slide 61: Priorities Going Forward

    61 PRIORITIES GOING FORWARD: (1) TWO DRUG CANDIDATES; (2) SEVEN INDICATIONS; (3) MULTIPLE COMBINATIONS • Prioritize First in Class and/or Best in Class • Consider potential for fast PoC & accelerated development paths AIM FOR LEADERSHIP • Macrophage & CD47 involvement • Preclinical and/or clinical P

  62. Slide 62: ~30K Addressable Patients Per Year in Entry Settings

    62 SIGNIFICANT OPPORTUNITY WITH ~30K ADDRESSABLE PATIENTS PER YEAR IN ENTRY SETTINGS (US) TTI-622 TTI-621 MM AML p53 mut AML Unfit Ovarian DLBCL PTCL LMS Entry setting 4L+ 1L 1L 2L+ PROC 2L+ 2L 1L Combination agent(s) Carf+dex Aza Aza+Ven Chemotx PD-1 [Monotx] Dox US Addressable Market (new pts, p.a

  63. Slide 63: Pipeline: Initiating P1b/2 Studies in Nine Settings

    63 PIPELINE: INITIATING P1B/2 STUDIES IN NINE SETTINGS PROGRAM INDICATION COMBINATION AGENT STAGE OF DEVELOPMENT SPONSOR STATUS PRECLINICAL IND ENABLING EARLY-STAGE CLINICAL LATE-STAGE CLINICAL 622 MM Carfilzomib+dex Trillium First patient dosed AML p53 mut. Azacitidine Trillium Enrolling AML unfit

  64. Slide 64: Treatment Landscape in Multiple Myeloma

    Treatment Landscape in Multiple Myeloma Alexander M. Lesokhin, MD Assistant Member Myeloma Service Cellular Therapeutics Center

  65. Slide 65: Burden of Myeloma

    Burden of Myeloma • 2nd most common hematologic malignancy • Myeloma in US – New Myeloma Cases in 2021 – 34,920 – Patients Living with Myeloma – 149,950 • Worldwide Incidence – 160,000 – Estimated ~750,000 living with Myeloma worldwide SEER 13. Deaths come from U.S. Mortality Ludwig et al., Oncologi

  66. Slide 66: Timeline of Myeloma Drug Discovery and Survival

    Timeline of myeloma drug discovery and relative survival over time Shah and Mailankody. BMJ 2020

  67. Slide 67: The Multiple Myeloma Space

    • MGUS The Multiple Myeloma Space • (SMM/H- SMM) • Observation • Symptomatic Myeloma • Transplant Candidates • Non-Transplant Candidates • Maintenance • Lenalidomide Exposed/Ref. • Frontline Treatment • Maintenance • Sensitive • Triple/Penta- Refractory • Refractory

  68. Slide 68: Carfilzomib or Anti-CD38 Therapy Earlier in Disease Course

    Myeloma Patients Will Now Receive Carfilzomib or Anti-CD38 mAb Therapy Earlier in Disease Course APOLLO Dara SC/Pom/dex Vs Pom/dex ICARIA-MM Isatux/Pom/dex vs Pom/dex CANDOR Dara IV/Carfil/dex vs Carfilz/dex IKEMA Isatux/Carfilz/dex vs Carfilz/dex N 151 vs 153 154 vs 153 312 vs 154 179 vs 123 Median

  69. Slide 69: Anti-CD38 Refractory Disease Represents Medical Need

    Myeloma Patients With Anti-CD38 Refractory Disease Represent an Area of Medical Need Gandhi et al. Leukemia 2019 Group (refractory definitions) OS (m) (95% CI) Not triple refractory (CD38, not both IMiD and PI) 11.2 (5.4-17.1) Triple/quad refractory (CD38, 1 or 2 IMiD, and 1 or 2 PI) 9.2 (7.1-11.2)

  70. Slide 70: The Multiple Myeloma Space: NCCN Guidelines

    MGUS The Multiple Myeloma Space NCCN Guidelines Multiple Myeloma. Version 3.2021. (SMM/H-SMM) Observation Symptomatic Myeloma 1 Category 1 recommendation Transplant Candidates Non-Transplant Candidates Maintenance Lenalidomide Exposed/Ref. Frontline Treatment Maintenance Sensitive Preferred Regimens

  71. Slide 71: Ide-cel: FDA Approved March 2021

    Idecabtagene vicleucel (ide-cel; bb2121): FDA Approved March 2021 Munshi, N. et al. ASCO 2020 ORR 82% CR/sCR 35%

  72. Slide 72: The Multiple Myeloma Space: NCCN Guidelines

    MGUS The Multiple Myeloma Space NCCN Guidelines Multiple Myeloma. Version 3.2021. (SMM/H-SMM) Observation Symptomatic Myeloma 1 Category 1 recommendation Transplant Candidates Non-Transplant Candidates Maintenance Lenalidomide Exposed/Ref. Frontline Treatment Maintenance Sensitive Preferred Regimens

  73. Slide 73: CD47 Expression Is Increased in Multiple Myeloma

    CD47 Expression Is Increased Multiple Myeloma Sun et al., Cancers 2020

  74. Slide 74: CD47 Expression and Disease Natural History

    CD47 Expression And Disease Natural History CD47 Expression Is Higher in Relapsed Myeloma Higher CD47 Expression Is Associated with Shortened Survival Rastgoo et al., Haematologica 2019

  75. Slide 75: Multiple Myeloma: Preclinical Monotherapy Activity Enhanced in Combo

    75 MULTIPLE MYELOMA: 622/621 HAS PRECLINICAL MONO- THERAPY ACTIVITY THAT IS ENHANCED IN COMBO IN VITRO 622 HAS MONOTHERAPY, ENHANCED WITH CARFILZOMIB IN VIVO 621 HAS MONOTHERAPY, ENHANCED WITH BORTEZOMIB -4 -2 0 2 4 6 0 100 200 300 TTI-622 (Log nM) P h a g o c y t o s i s I n d e x TTI-622 EC50=9.21

  76. Slide 76: TTI-622 + Carf+Dex in Advanced Multiple Myeloma

    76 622 + CARF+DEX IN ADVANCED MULTIPLE MYELOMA Primary endpoint: ORR Key secondary endpoints: DoR, PFS, MRD PROOF OF CONCEPT TRIAL DOSE SELECTION TTI-622 + carfilzomib + dexamethasone N=~30 patients PATIENT POPULATION: > 3 PRIOR LINES OF THERAPY, REFRACTORY TO CARFILZOMIB 8 mg/kg Rationale for indic

  77. Slide 77: 621/622 + Dara in MM

    77 621/622 + DARA IN MM (IST WITH DR. LESOKHIN, MSKCC) PATIENT POPULATION: IMiD/PROTEASOME INHIBITOR EXPOSED, ANTI-CD38 REFRACTORY Rationale for indication and combination • Strong preclinical evidence for role of CD47 in Multiple Myeloma; CD47 demonstrated prognostic value • Dara and other CD38s ar

  78. Slide 78: AML 2021 and Beyond

    Trillium R & D Day AML 2021 and Beyond April 2021 Naval Daver, MD Director, Leukemia Research Alliance Program, Associate Professor Department of Leukemia MD Anderson Cancer Center

  79. Slide 79: Disclosures

    Disclosures Research Funding: Pfizer, BMS, Novartis, Servier, Daiichi- Sankyo, Karyopharm, Incyte, Abbvie, Genentech, Astellas, Immunogen, Forty-Seven, Amgen, Trovagene, Novimmune Advisory/Consulting: Pfizer, BMS, Daiichi-Sankyo, Novartis, Jazz, Astellas, Abbvie, Genentech, Agios, Servier, Immunogen

  80. Slide 80: Treatment of AML: History

    Treatment of AML (accelerated progress 2017–2020): History Year 1975 1980 1990 1995 2000 2005 2009 2013 2022 5-year survival 6.3% 6.8% 11.4% 17.3% 16.8% 25.7% 28.1% 27% ?? HSCT is introduced for AML All-trans retinoic acid (ATRA) FDA approved for APL 2020 1973 7+3 induction regimen introduced 1977 1

  81. Slide 81: HMA-Based Therapies for Older AML

    HMA-Based Therapies for Older AML Hypomethylating Agents Are Well Tolerated and Safe in Older Patients but Modest Single-Agent CR/CRi CR/CRi = 27% Dombret H, et al. Blood. 2015;36126(3):291-299.

  82. Slide 82: Azacitidine +/- Venetoclax (VIALE-A) Study Design

    Azacitidine +/- Venetoclax (VIALE-A) Study Design • 82 Randomization 2:1 N=433* Venetoclax + Azacitidine (N=286) Venetoclax 400 mg PO, daily, days 1–28 + Azacitidine 75 mg/m2 SC /IV days 1–7 Placebo + Azacitidine (N=145) Placebo daily, days 1–28 + Azacitidine 75 mg/m2 SC /IV days 1–7 DiNardo EHA 201

  83. Slide 83: Aza +/- Ven in AML: Composite Response Rate

    AZA+/- VEN in AML --Composite Response Rate (CR+CRi) • 83 *CR+CRi rate, CR rate, and CR+CRi by initiation of cycle 2 are statistically significant with p<0.001 by CMH test No. of treatment cycles, median (range) Median time to CR/CRi, Months (range) *CR+CRi by initiation of Cycle 2, n (%) Aza+Ven (n

  84. Slide 84: Aza +/- Ven in AML: Overall Survival

    AZA+/- VEN in AML -- Overall Survival • 84 No. of events/No. of patients (%) Median duration of study treatment, months (range) Median overall survival, months (95% CI) Aza+Ven 161/286 (56) 7.6 (<0.1 – 30.7) 14.7 (11.9 – 18.7) Aza+Pbo 109/145 (75) 4.3 (0.1 – 24.0) 9.6 (7.4 – 12.7) Hazard ratio: 0.66

  85. Slide 85: Molecular Determinants of Outcome With Venetoclax Combos

    Molecular Determinants of Outcome With Venetoclax Combos Patients treated at MDACC and The Alfred (n = 81) DiNardo CD, et al. Blood. 2020;135(11):791-803. Durable remissions with NPM1 and IDH2 (not IDH1?) - MRD clearance of NPM1 common by RT-PCR Resistance commonly associated with expansion or acqui

  86. Slide 86: Poor Outcomes in TP53 Mutant AML

    Poor Outcomes in TP53 Mutant AML, Even With Venetoclax-Based Treatment • 1. Chyla BJ et al. ASH 2019. Abstract 546. 2. Kim K, et al. ASH 2020. Abstract 693. N = 121 patients with newly diagnosed AML receiving decitabine + venetoclax2 • Those with TP53mut had a lower rate of CR at 35% vs 57% in pts w

  87. Slide 87: Magrolimab + AZA Induces High Response Rates in AML

    87 Magrolimab + AZA Induces High Response Rates in AML Response assessments per 2017 AML ELN criteria. Patients with at least 1 post-treatment response assessment are shown. *Three patients not shown due to missing values; <5% blasts imputed as 2.5%. 1. Fenaux P, et al. J Clin Oncol. 2010;28(4):562-

  88. Slide 88: Magrolimab + Azacitidine Is Well Tolerated

    88 Date: June 14, 2020; Program Section: 10. Myelodysplastic syndromes - Clinical Magrolimab in Combination With Azacitidine Is Well Tolerated • No maximum tolerated dose was reached; magrolimab + AZA profile consistent with AZA monotherapy • No significant worsening of cytopenias, infections, or au

  89. Slide 89: Preliminary Median Overall Survival Encouraging

    89 Preliminary Median Overall Survival Is Encouraging in Both TP53 Wild-Type and Mutant Patients NE, not evaluable. 1. DiNardo CD, et al. N Eng J Med. 2020;383(7):617-629. 2. Kim K, et al. Poster presented at: 62nd ASH Annual Meeting; December 5-8, 2020 (virtual). 3. DiNardo CD, et al. Blood. 2019;1

  90. Slide 90: TTI-622 + Aza in 1L AML p53 Mutant Patients

    90 622 + AZA IN 1L AML P53 MUT PATIENTS PROOF OF CONCEPT TRIAL DOSE SELECTION TTI-622 + azacitidine N=~25 patients PATIENT POPULATION: P53 MUTATION, NEWLY-DIAGNOSED Primary endpoint: CR rate Key secondary endpoints: DoR, EFS, MRD 8 mg/kg 1L Aza monotx CR rate ~ 25% Rationale for indication and combi

  91. Slide 91: TTI-622 + Aza + Ven in AML Unfit 1L

    91 622 + AZA + VEN IN AML UNFIT 1L (P53 WT) PROOF OF CONCEPT TRIAL DOSE SELECTION TTI-622 + azacitidine + venetoclax N=~50 patients PATIENT POPULATION: P53 WILD-TYPE, NEWLY-DIAGNOSED, ELDERLY OR UNFIT FOR MORE AGGRESSIVE TREATMENT Primary endpoint: CR rate Key secondary endpoints: DoR, EFS, MRD 8 mg

  92. Slide 92: DLBCL

    92 DLBCL ~40% of patients relapse or are refractory to 1L Standard of care in 1L consists of R-CHOP with impressive response rates. In 2L, ASCT is recommended for eligible patients, and new biologic therapies have recently been approved in transplant ineligible patients. CAR-T, ADCs & other agents a

  93. Slide 93: 622/621 + PD-1 in DLBCL

    93 622/621 + PD-1 IN DLBCL (IST WITH DR. ANSELL, MAYO) PROOF OF CONCEPT TRIAL DOSE SELECTION TTI-621 + PD-1 N=~25 patients PATIENT POPULATION: PATIENTS WITH RELAPSED/REFRACTORY DLBCL WHO PROGRESSED AFTER AT LEAST 1 LINE OF SYSTEMIC THERAPY 1.4 mg/kg 621 + 200 mg PD-1 2 mg/kg 621 + 200 mg PD-1 Primar

  94. Slide 94: Leiomyosarcoma (LMS)

    94 LEIOMYOSARCOMA (LMS) Trillium has decided to focus on the largest STS subtype, Leiomyosarcoma (LMS), where there is good preclinical CD47 rationale. Standard of care for 1L metastasized disease is radiation and doxorubicin. Trillium will focus on improving the quality and duration of response for

  95. Slide 95: TTI-621 + Doxorubicin Clinical Development Plan

    95 621 + DOXORUBICIN CLINICAL DEVELOPMENT PLAN PROOF OF CONCEPT TRIAL DOSE ESCALATION TTI-621 low dose (0.2 mg/kg) + doxorubicin 75 mg/m2 N=~30 patients TTI-621 high dose (up to 2.0 mg/kg) + doxorubicin 75 mg/m2 N=~30 patients 0.2 mg/kg N=3-6 0.7 mg/kg N=3-6 2.0 mg/kg N=3-6 PATIENT POPULATION: FRONT

  96. Slide 96: Ovarian Cancer

    96 Most patients are diagnosed with advanced stage disease OVARIAN CANCER Standard of care for 2L+ will include a combination of chemotherapy, Avastin and PARP inhibitors, with or without platinum agents. Trillium will focus on improving the quality, quantity and duration of response for platinum-re

  97. Slide 97: Peripheral T Cell Lymphoma (PTCL)

    97 PERIPHERAL T CELL LYMPHOMA (PTCL) In western countries, the three most common subtypes are Not Otherwise Specified (NOS), Angioimmunoblastic (AITL), and the combination of ALK+ and ALK- Anaplastic Large Cell Lymphoma (ALCL). Standard of care includes 1L chemo (+/- Adcetris). In the R/R setting, p

  98. Slide 98: Strategic Priorities: Key Takeaways

    98 STRATEGIC PRIORITIES: KEY TAKEAWAYS Both TTI-622 and 621 to advance into P1b/2, primarily in combinations with other agents 1 Initiating new P1b/2 studies in seven target indications (nine patient settings) 2 Portfolio of multiple shots on goal across hemes and solids, with different risk/return

  99. Slide 99: Program Timeline and Milestones

    99 PROGRAM TIMELINE MILESTONE 622 Initiate carf combo in multiple myeloma 2Q21 Initiate aza combo in AML p53mut 2Q21 Initiate aza+ven combo in AML unfit 1L 2H21 Data update on dose escalation in lymphomas at a medical meeting 2H21 Provide detail on design and initiate ovarian cancer study 4Q21-1H22

  100. Slide 100: Wrap-Up: Two Key Takeaways

    100 WRAP-UP: TWO KEY TAKEAWAYS Monotx PoC in hemes Combination regimens Solid tumors Q2/3W dosing + Strong basis for Organization set up for success + Robust foundation with monotherapy PoC at its core 1 Clear path forward with multiple shots on goal (2 drug candidates, 7 indications) 2 INDICATION C

  101. Slide 101: Q&A

    101 Q&A pt 2 CEO Jan Skvarka CMO Ingmar Bruns SVP, Corp Dev and Strategy Rose Harrison CDO Penka Petrova CFO James Parsons CSO Bob Uger KOL Naval Daver KOL Alex Lesokhin

  102. Slide 102: Thank You

    CAMBRIDGE OFFICE 100 Cambridgepark Drive Suite 510 Cambridge, MA 02140 USA Tel: +1 857.412.7029 MISSISSAUGA OFFICE 2488 Dunwin Drive Mississauga, ON L5L 1J9 Canada Tel: +1 416.595.0627 THANK YOU JOIN THE TEAM careers@trilliumtherapeutics.com COLLABORATE collaborations@trilliumtherapeutics.com INVEST

  103. Slide 103: Appendix

    103 APPENDIX • Receptor Occupancy considerations • Preclinical data for target indications

  104. Slide 104: Receptor Occupancy: PD Biomarker of Exposure, Not Clinical Activity

    104 RECEPTOR OCCUPANCY (RO) – A PD BIOMARKER OF EXPOSURE BUT NOT CLINICAL ACTIVITY • We measure RO on peripheral blood T cells and the correlation with tumor occupancy is not known; peripheral RO may substantially underestimate RO on tumor cells expressing higher levels of CD47 • For TTI-622/621, pe

  105. Slide 105: Measuring RO on Normal T Cells May Underestimate RO on Tumor Cells

    105 MEASURING 622/621 RO ON NORMAL T CELLS MAY UNDERESTIMATE RO ON TUMOR CELLS Receptor Occupancy CD47 Expression • 50% RO on CD47-high expressing tumor target achieved with 10x less drug compared to normal T cells with lower CD47 • Preference for cells with high target expression likely due to mode

  106. Slide 106: RO on Peripheral T Cells Correlates With Exposure

    106 RO ON PERIPHERAL T CELLS CORRELATES WITH EXPOSURE ULOQ: Upper limit of quantitation EOI: End of infusion

  107. Slide 107: RO on Peripheral T Cells Does Not Correlate With Clinical Activity

    107 RO ON PERIPHERAL T CELLS DOES NOT CORRELATE WITH CLINICAL ACTIVITY TTI-621 TTI-622 Peak RO Wk6 Baseline Peak RO Wk6 Baseline

  108. Slide 108: Nivolumab and Pembrolizumab Case Studies

    108 NIVOLUMAB AND PEMBROLIZUMAB CASE STUDIES: RO NOT USEFUL FOR DOSE SELECTION • Nivolumab: o Activity across multiple dose levels o No MTD identified o 65-70% trough RO on circulating CD3+ T cells at 0.3-10 mg/kg dose levels o 3 mg/kg selected based on integrated dose-response/exposure-response ana

  109. Slide 109: 40-60% RO Results in Robust Macrophage Phagocytosis

    109 40-60% RO RESULTS IN ROBUST MACROPHAGE PHAGOCYTOSIS Source: Liu et al. 2015 PLoS ONE 10:e0137345 Magrolimab Maximal phagocytosis at 40-60% RO EC50 at ~20% RO EC90 at ~70% RO TTI-621 0 10 20 30 40 50 60 70 80 90 100 0 10 20 30 40 50 60 70 80 90 100 Phagcoytosis vs Receptor Occupancy % Receptor Oc

  110. Slide 110: Appendix

    110 APPENDIX • Receptor Occupancy considerations • Preclinical data for target indications

  111. Slide 111: Ovarian Cancer: Monotherapy in Preclinical Models

    111 OVARIAN CANCER: 621 SHOWN MONOTHERAPY IN PRECLINICAL MODELS 621 MONOTHERAPY IN SKOV-3 MODEL A B C D 621 MONOTHERAPY IN OVCAR-3 MODEL

  112. Slide 112: Sarcoma: Published Research Suggests Promise for CD47 Therapies in LMS

    112 SARCOMA: PUBLISHED RESEARCH SUGGESTS PROMISE FOR CD47 THERAPIES IN LMS ANTI-CD47 DECREASED PRIMARY TUMOR AND METASTASES IN LMS XENOGRAFTS Source: Edris et al., 2012 PNAS A B C D E

Trillium Therapeutics — Investor Day (April 2021) on 6ix